Post-progression survival in advanced non-small cell lung cancer treated with anti-PD-1/PDL-1 monotherapy: progression after durable clinical benefit versus primary resistance

Ivan Pourmir, Reza Elaidi, Zineb Maaradji, Hortense de Saint Basile, Monivann Ung, Benoit Gazeau, Laure Fournier, Bastien Rance, Laure Gibault, Mohammed Ismaili, Elizabeth Fabre
doi: https://doi.org/10.1101/2023.03.09.23287023

Article usage

Article usage: March 2023 to November 2024

AbstractFullPdf
Mar 2023370779
Apr 202358119
May 202338117
Jun 20233659
Jul 20232718
Aug 202323129
Sep 20232249
Oct 20231152
Nov 20232684
Dec 20231105
Jan 20241527
Feb 20241654
Mar 20242185
Apr 2024976
May 20241224
Jun 20241608
Jul 202415211
Aug 2024411
Sep 20241558
Oct 2024516
Nov 2024707
Back to top
Posted March 13, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Post-progression survival in advanced non-small cell lung cancer treated with anti-PD-1/PDL-1 monotherapy: progression after durable clinical benefit versus primary resistance
Ivan Pourmir, Reza Elaidi, Zineb Maaradji, Hortense de Saint Basile, Monivann Ung, Benoit Gazeau, Laure Fournier, Bastien Rance, Laure Gibault, Mohammed Ismaili, Elizabeth Fabre
medRxiv 2023.03.09.23287023; doi: https://doi.org/10.1101/2023.03.09.23287023
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area